Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Steroidogenesis Inhibitors (STGI) -- Ignore unavailable to you. Want to Upgrade?

To: Jim Burnham who wrote (131)	9/18/1999 12:10:00 PM
From: SCOOBEY-DO	Respond to of 294

I found this interesting in the 10SB that was issued on 7/21/99: As of June 30, 1999, there were 15,438,128 shares of common stock issued and outstanding. Of those shares 13,114,104 shares are "restricted" securities of the Company within the meaning of Rule 144(a)(3) promulgated under the Securities Act of 1933, as amended, because such shares were issued and sold by the Company in private transactions not involving a public offering. Of these restricted securities, 9,394,512 shares held by affiliates may be sold pursuant to a registration statement or pursuant to Rule 144. That means that STGI's current float is only 2,324,024.

To: Jim Burnham who wrote (131)	9/23/1999 3:52:00 PM
From: SCOOBEY-DO	Read Replies (1) \| Respond to of 294

September 23, 1999 15:40 Steroidogenesis Inhibitors International is Now a Reporting Company LAS VEGAS--(BW HealthWire)--Sept. 23, 1999--Dr. Alfred T. Sapse, President of Steroidogenesis Inhibitors International (OTC BB: STGI), announced today that on September 19, 1999, the Company became a reporting company upon the effectiveness of its registration statement on Form 10-SB filed with the United States Securities and Exchange Commission for the registration of its common stock under Section 12(g) of the Securities Exchange Act of 1934. Dr. Sapse noted that despite the effectiveness of its registration statement, the Company still has the task of responding to SEC staff comments on the registration statement. The Company intends to respond by September 30, 1999. STGI is a pharmaceutical company engaged in the field of developing anti-cortisol drugs intended for the treatment of diseases associated with elevated levels of cortisol, aging, cancers, and Alzheimer's included. This release may include forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct. This is neither an offer to buy or sell a security. For more information visit our World Wide Web page at anticort.com. CONTACT: Steroidogenesis Janet Greeson, Ph.D., 702/221-0409 or Performance Strategies, Inc. Richard L. Brown/Charles E.(Chuck) Jordan, Sr. 303/948-3601